Novartis prioritises Antisoma's ASA404 in breast cancer ahead of prostate cancer
This article was originally published in Scrip
Executive Summary
Novartis is to evaluate Antisoma's tumour-vascular disrupting agent ASA404 in what is rumoured to be a Phase II/III trial for HER2-negative metastatic breast cancer.